Xiao Zhen Zhou

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2064403/publications.pdf

Version: 2024-02-01

159585 197818 4,548 50 30 49 citations h-index g-index papers 51 51 51 4818 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The Pin1-CaMKII-AMPA Receptor Axis Regulates Epileptic Susceptibility. Cerebral Cortex, 2021, 31, 3082-3095.	2.9	6
2	Sulfopin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivo. Nature Chemical Biology, 2021, 17, 954-963.	8.0	73
3	Cis P-tau underlies vascular contribution to cognitive impairment and dementia and can be effectively targeted by immunotherapy in mice. Science Translational Medicine, 2021, 13, .	12.4	34
4	Inhibition of death-associated protein kinase 1 attenuates cis P-tau and neurodegeneration in traumatic brain injury. Progress in Neurobiology, 2021, 203, 102072.	5.7	22
5	Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy. Cell, 2021, 184, 4753-4771.e27.	28.9	99
6	Cobalt induces neurodegenerative damages through Pin1 inactivation in mice and human neuroglioma cells. Journal of Hazardous Materials, 2021, 419, 126378.	12.4	25
7	PIN1 Inhibition Sensitizes Chemotherapy in Gastric Cancer Cells by Targeting Stem Cell–like Traits and Multiple Biomarkers. Molecular Cancer Therapeutics, 2020, 19, 906-919.	4.1	18
8	Melatonin directly binds and inhibits deathâ€associated protein kinase 1 function in Alzheimer's disease. Journal of Pineal Research, 2020, 69, e12665.	7.4	37
9	Identification of a potent and selective covalent Pin1 inhibitor. Nature Chemical Biology, 2020, 16, 979-987.	8.0	40
10	Inactivation of the Prolyl Isomerase Pin1 Sensitizes BRCA1-Proficient Breast Cancer to PARP Inhibition. Cancer Research, 2020, 80, 3033-3045.	0.9	23
11	Targeting PIN 1 exerts potent antitumor activity in pancreatic ductal carcinoma via inhibiting tumor metastasis. Cancer Science, 2019, 110, 2442-2455.	3.9	9
12	Death-Associated Protein Kinase 1 Phosphorylation in Neuronal Cell Death and Neurodegenerative Disease. International Journal of Molecular Sciences, 2019, 20, 3131.	4.1	56
13	An IRAK1–PIN1 signalling axis drives intrinsic tumour resistance to radiation therapy. Nature Cell Biology, 2019, 21, 203-213.	10.3	38
14	Traumatic Brain Injury-related voiding dysfunction in mice is caused by damage to rostral pathways, altering inputs to the reflex pathways. Scientific Reports, 2019, 9, 8646.	3.3	13
15	Pin1 inhibition potently suppresses gastric cancer growth and blocks PI3K/AKT and Wnt/βâ€catenin oncogenic pathways. Molecular Carcinogenesis, 2019, 58, 1450-1464.	2.7	24
16	Targeting Pin1 by All-Trans Retinoic Acid (ATRA) Overcomes Tamoxifen Resistance in Breast Cancer via Multifactorial Mechanisms. Frontiers in Cell and Developmental Biology, 2019, 7, 322.	3.7	19
17	Pin1 inhibition reverses the acquired resistance of human hepatocellular carcinoma cells to Regorafenib via the Gli1/Snail/E-cadherin pathway. Cancer Letters, 2019, 444, 82-93.	7.2	35
18	The IL-33-PIN1-IRAK-M axis is critical for type 2 immunity in IL-33-induced allergic airway inflammation. Nature Communications, 2018, 9, 1603.	12.8	58

#	Article	IF	Citations
19	"Tau immunotherapy: Hopes and hindrances― Human Vaccines and Immunotherapeutics, 2018, 14, 277-284.	3.3	15
20	A novel controlled release formulation of the Pin1 inhibitor ATRA to improve liver cancer therapy by simultaneously blocking multiple cancer pathways. Journal of Controlled Release, 2018, 269, 405-422.	9.9	49
21	Targeting Prion-like Cis Phosphorylated Tau Pathology in Neurodegenerative Diseases. , 2018, 08, .		12
22	Pin1 inhibition exerts potent activity against acute myeloid leukemia through blocking multiple cancer-driving pathways. Journal of Hematology and Oncology, 2018, 11, 73.	17.0	23
23	Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells. Nature Communications, 2018, 9, 3069.	12.8	116
24	Pin1 Knockout Mice: A Model for the Study of Tau Pathology in Alzheimer's Disease. Methods in Molecular Biology, 2017, 1523, 415-425.	0.9	7
25	Cis P-tau is induced in clinical and preclinical brain injury and contributes to post-injury sequelae. Nature Communications, 2017, 8, 1000.	12.8	103
26	Function and regulation of tau conformations in the development and treatment of traumatic brain injury and neurodegeneration. Cell and Bioscience, 2016, 6, 59.	4.8	35
27	G Protein-coupled Receptor Kinase 2 (GRK2) Promotes Breast Tumorigenesis Through a HDAC6-Pin1 Axis. EBioMedicine, 2016, 13, 132-145.	6.1	53
28	The role of Pin1 in the development and treatment of cancer. Archives of Pharmacal Research, 2016, 39, 1609-1620.	6.3	32
29	Potential of the Antibody Against <i>cis</i> –Phosphorylated Tau in the Early Diagnosis, Treatment, and Prevention of Alzheimer Disease and Brain Injury. JAMA Neurology, 2016, 73, 1356.	9.0	64
30	The isomerase PIN1 controls numerous cancer-driving pathways and is a unique drug target. Nature Reviews Cancer, 2016, 16, 463-478.	28.4	209
31	Prolyl Isomerase Pin1 Regulates Axon Guidance by Stabilizing CRMP2A Selectively in Distal Axons. Cell Reports, 2015, 13, 812-828.	6.4	39
32	The Rab2A GTPase Promotes Breast Cancer Stem Cells and Tumorigenesis via Erk Signaling Activation. Cell Reports, 2015, 11, 111-124.	6.4	80
33	Pin1 cysteine-113 oxidation inhibits its catalytic activity and cellular function in Alzheimer's disease. Neurobiology of Disease, 2015, 76, 13-23.	4.4	91
34	Pin1 dysregulation helps to explain the inverse association between cancer and Alzheimer's disease. Biochimica Et Biophysica Acta - General Subjects, 2015, 1850, 2069-2076.	2.4	84
35	Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy. Nature, 2015, 523, 431-436.	27.8	374
36	Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer. Nature Medicine, 2015, 21, 457-466.	30.7	220

#	Article	IF	Citations
37	ATR Plays a Direct Antiapoptotic Role at Mitochondria, which Is Regulated by Prolyl Isomerase Pin1. Molecular Cell, 2015, 60, 35-46.	9.7	71
38	Prolyl Isomerase Pin1 Acts Downstream of miR200c to Promote Cancer Stem–like Cell Traits in Breast Cancer. Cancer Research, 2014, 74, 3603-3616.	0.9	68
39	The prolyl isomerase Pin1 regulates hypoxia-inducible transcription factor (HIF) activity. Cellular Signalling, 2014, 26, 1649-1656.	3.6	17
40	Proline Isomer-Specific Antibodies Reveal the Early Pathogenic Tau Conformation in Alzheimer's Disease. Cell, 2012, 149, 232-244.	28.9	232
41	The telomerase inhibitor PinX1 is a major haploinsufficient tumor suppressor essential for chromosome stability in mice. Journal of Clinical Investigation, 2011, 121, 1266-1282.	8.2	52
42	PinX1: a sought-after major tumor suppressor at human chromosome 8p23. Oncotarget, 2011, 2, 810-819.	1.8	16
43	O4-04-01: Pin1 protects against tau and Abeta-related pathologies and delays onset of Alzheimer's disease. , 2010, 6, S154-S155.		2
44	The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease. Nature Reviews Molecular Cell Biology, 2007, 8, 904-916.	37.0	606
45	Role of Pin2/TRF1 in telomere maintenance and cell cycle control. Journal of Cellular Biochemistry, 2003, 89, 19-37.	2.6	30
46	Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration. Nature, 2003, 424, 556-561.	27.8	412
47	Involvement of the telomeric protein Pin2/TRF1 in the regulation of the mitotic spindle. FEBS Letters, 2002, 514, 193-198.	2.8	31
48	Binding and regulation of the transcription factor NFAT by the peptidyl prolyl cis -trans isomerase Pin1. FEBS Letters, 2001, 496, 105-108.	2.8	45
49	Accumulation of rab4GTP in the Cytoplasm and Association with the Peptidyl-Prolyl Isomerase Pin1 during Mitosis. Molecular Biology of the Cell, 2000, 11, 2201-2211.	2.1	42
50	The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature, 1999, 399, 784-788.	27.8	687